Inventor · disambiguated record
Michael Byrne
Also filed as: BYRNE MICHAEL · BYRNE MICHAEL C · BYRNE MICHAEL CHAPMAN
5 granted patents·7 pending applications·347 citations·filing 2001–2016
80Inventor score
Top patents by PatentIndex Score
12 records- 0195US7618632B2Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodiesWYETH CORP·Filed 2004·Granted Nov 17, 2009·326 cites·4 claims
- 0291US11001845B2Nucleic acid molecules targeting superoxide dismutase 1 (SOD1)PHIO PHARM CORP·Filed 2016·Granted May 11, 2021·7 cites·6 claims
- 0384US10808247B2Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approachPHIO PHARM CORP·Filed 2016·Granted Oct 20, 2020·9 cites·14 claims
- 0483US11279934B2Methods for treating cancer using nucleic acids targeting MDM2 or MYCNPHIO PHARM CORP·Filed 2015·Granted Mar 22, 2022·5 cites·8 claims
- 0557US2010080809A1Gitr ligand and gitr ligand-related molecules and antibodies and uses thereofWYETH CORP·Filed 2009·Application pending·0 cites
- 0655US2008221016A1Cd25+ differential markers and uses thereofWYETH CORP·Filed 2008·Application pending·0 cites
- 0752US2003133936A1CD25markers and uses thereofFiled 2002·Application pending·0 cites
- 0843US2005164233A1Compositions, kits and methods for identification and modulation of type I diabetesFiled 2004·Application pending·0 cites
- 0938US2003064380A1Anergy-regulated moleculesBLOOD RES CENTER·Filed 2002·Application pending·0 cites
- 1035US2002039736A1Compositions, kits, and methods for identification and modulation of type I diabetesFiled 2001·Application pending·0 cites
- 1133US9637795B2Methods and compositions for predicting response to eribulinAGOULNIK SERGEI I·Filed 2012·Granted May 2, 2017·0 cites·20 claims
- 1233US2017051290A1Methods for treatment of disorders in the front of the eye utilizing nucleic acid moleculesRXI PHARMACEUTICALS CORP·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michael Byrne files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →